SysMedPD started in December 2015 to further explore and identify novel drug candidates capable of slowing down the progression of neurodegeneration in the subset of PD patients with overt mitochondrial dysfunction. After Alzheimer’s disease, Parkinson’s disease (PD) is the second most common neurodegenerative disease and its prevalence will continue to grow as the population ages. More than one million people with PD live in Europe today and this number is forecast to double by 2030. The consortium’s objectives are to improve means for PD detection and therapy development by developing tools and approaches, and to commercialize the project results so the society as a whole can benefit from the results. The interview clips illustrate the interdisciplinary approach of the multi-national consortium and showcase the different expertise the partners bring to the project including their personal motivation to achieve the project’s objectives. The SysMedPD partners can build on the scientific expertise of an outstanding consortium of complementary academic groups as well as biopharmaceutical companies with longstanding expertise in the field of mitochondrial medicine and drug testing. Equipped with a budget of €5.9 million, the project is funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668738.
Germany, Ireland, Luxembourg, Netherlands, United Kingdom